Immuneering Corp (IMRX) News
Filter IMRX News Items
IMRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMRX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest IMRX News From Around the Web
Below are the latest news stories about IMMUNEERING CORP that investors may wish to consider to help them evaluate IMRX as an investment opportunity.
Why Is Immuneering Stock Trading Higher On Tuesday?On Tuesday, Immuneering Corporation (NASDAQ:IMRX) revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a trial to include three additional combination arms. Updated data from the Phase 2a arm of IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer shows: As of December 5, 2024, three patients achieved complete or partial responses for an overall response rate of 43% (3/7) and a |
Immuneering Says New Phase 2a Pancreatic Cancer Trial Data Show Better Response, Disease Control RatesImmuneering (IMRX) said Tuesday that new data from an ongoing phase 2a trial of its lead candidate I |
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway - - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) - - Encouraging initial dat |
Aadi Bioscience Leads 3 Promising US Penny StocksAs the U.S. stock market navigates a challenging week marked by encouraging inflation data yet overall losses, investors are exploring diverse opportunities to mitigate risk and capitalize on potential gains. Penny stocks, often associated with smaller or newer companies, continue to attract attention due to their potential for significant returns when backed by strong financial health. Despite being considered a niche area of investment today, these stocks can offer intriguing opportunities... |
Immuneering Launches Pancreatic Cancer Advisory Board- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 - CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced th |
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer - - The company will also provide initial data from IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer, as well as IMM-1-104 monotherapy in second-line pancreatic cancer - CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to |
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares. The analyst downgraded the stock to Equal-weight from Overweigh |
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma - - Melanoma patients actively enrolling in one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX |
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare ConferenceCAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Palace in New York City from December 3-5, 2024, to discuss the company’s pipeline, platform, and business strategy. Parti |
Immuneering Leads The Pack Of 3 US Penny Stocks To MonitorAs the U.S. stock market experiences a positive uptick with major indices like the Dow Jones and S&P 500 showing gains, investors are increasingly looking for opportunities beyond traditional blue-chip stocks. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing possibilities for those willing to explore beyond well-known names. Despite being considered a niche area of investment today, these stocks can still present significant growth potential when... |